Patient characteristics
Patient . | Sex/age, y . | Stage . | FACS analysis with anti-BV AB (% of BV + CD4 T cells) . | Antibodies, CD4 count/mm3 . | CD4/CD8 ratio . | Disease duration . | Current treatment . | Previous treatment . |
|---|---|---|---|---|---|---|---|---|
| Numerically expanded clone | ||||||||
| 1 | M/68 | IVB | BV 5.1 (73) | 538 | 2 | 1 y | PDN; topical steroids | MTX; UVB; etanercept (for concurrent arthritis) |
| 2 | F/50 | IVA | BV 14 (81) | 1293 | 14 | 3 y | Topical steroids; antihistamines | Topical steroids |
| 3 | M/50 | III | BV 18 (94) | 1727 | 13.5 | 4-5 y | 12 cycles ECP; MTX | PUVA; topical steroids |
| 4 | F/94 | III | BV 2 (96) | 8251 | 37.3 | 3 y | Topical steroids; antihistamines | PUVA; MTX, 25 mg |
| 5 | M/76 | III | BV 20 (93.6) | 838 | 13.3 | 5 y | 4 cycles ECP; IFN-α | Bexarotene; denileukin diftitox |
| 6 | F/72 | III | BV 1 (87) | 5965 | 7.9 | 3 y | 10 cycles ECP; bexarotene | Topical steroids; topical tacrolimus |
| Without an identifiable expanded population | ||||||||
| 7 | F/58 | IVA | No clone detectable | 223 | 4.4 | 5-6 y | 18 cycles ECP; IFN-α | Bexarotene; denileukin diftitox |
| 8 | M/61 | IV | No clone detectable | 1019 | 7.4 | 7 y | 4 cycles ECP; PDN | PUVA; IFN, total skin electron beam; bexarotene |
| 9 | M/74 | III | No clone detectable | 264 | 3.4 | 4 y | 6 cycles of ECP; topical steroids | Narrow UVB |
| 10 | M/59 | III | No clone detectable | 1005 | 2.1 | 6 mo | UVB (3 × wk) | None |
| 11 | M/72 | IB | No clone detectable | 701 | 7.2 | 4 y | 9 cycles ECP | PUVA |
| 12 | M/64 | IB | No clone detectable | 505 | 1.8 | 4 y | PUVA (2 × wk) | Topical steroids; nitrogen mustard |
| 13 | M/73 | IB | No clone detectable | 624 | 1.75 | 3 y | Denileukin diftitox | Denileukin diftitox; topical steroids; topical calcipotriol |
| 14 | M/70 | IIB | No clone detectable | 255 | 3.4 | 8 y | Topical steroids | PUVA; MTX; electron beam; ECP |
| 15 | F/53 | IB | No clone detectable | 811 | 1.2 | 5 y | Topical steroids and tacrolimus | PUVA; denileukin diftitox |
| 16 | M/77 | IB | No clone detectable | 443 | 1.1 | 3 y | Topical steroids | Topical steroids |
| 17 | F/30 | IA | No clone detectable | 460 | 0.5 | 3 y | Topical steroids | None |
| 18 | F/44 | IA | No clone detectable | 819 | 4.0 | 5 y | Topical steroids; MTX | Topical steroids |
| 19 | F/57 | IA | Not done | Not done | Not done | 10 y | No therapy (in spontaneous remission for 10 y) | None |
| 20 | F/60 | IA | Not done | Not done | Not done | 5 y | PUVA every 2 weeks | PUVA; topical steroids |
Patient . | Sex/age, y . | Stage . | FACS analysis with anti-BV AB (% of BV + CD4 T cells) . | Antibodies, CD4 count/mm3 . | CD4/CD8 ratio . | Disease duration . | Current treatment . | Previous treatment . |
|---|---|---|---|---|---|---|---|---|
| Numerically expanded clone | ||||||||
| 1 | M/68 | IVB | BV 5.1 (73) | 538 | 2 | 1 y | PDN; topical steroids | MTX; UVB; etanercept (for concurrent arthritis) |
| 2 | F/50 | IVA | BV 14 (81) | 1293 | 14 | 3 y | Topical steroids; antihistamines | Topical steroids |
| 3 | M/50 | III | BV 18 (94) | 1727 | 13.5 | 4-5 y | 12 cycles ECP; MTX | PUVA; topical steroids |
| 4 | F/94 | III | BV 2 (96) | 8251 | 37.3 | 3 y | Topical steroids; antihistamines | PUVA; MTX, 25 mg |
| 5 | M/76 | III | BV 20 (93.6) | 838 | 13.3 | 5 y | 4 cycles ECP; IFN-α | Bexarotene; denileukin diftitox |
| 6 | F/72 | III | BV 1 (87) | 5965 | 7.9 | 3 y | 10 cycles ECP; bexarotene | Topical steroids; topical tacrolimus |
| Without an identifiable expanded population | ||||||||
| 7 | F/58 | IVA | No clone detectable | 223 | 4.4 | 5-6 y | 18 cycles ECP; IFN-α | Bexarotene; denileukin diftitox |
| 8 | M/61 | IV | No clone detectable | 1019 | 7.4 | 7 y | 4 cycles ECP; PDN | PUVA; IFN, total skin electron beam; bexarotene |
| 9 | M/74 | III | No clone detectable | 264 | 3.4 | 4 y | 6 cycles of ECP; topical steroids | Narrow UVB |
| 10 | M/59 | III | No clone detectable | 1005 | 2.1 | 6 mo | UVB (3 × wk) | None |
| 11 | M/72 | IB | No clone detectable | 701 | 7.2 | 4 y | 9 cycles ECP | PUVA |
| 12 | M/64 | IB | No clone detectable | 505 | 1.8 | 4 y | PUVA (2 × wk) | Topical steroids; nitrogen mustard |
| 13 | M/73 | IB | No clone detectable | 624 | 1.75 | 3 y | Denileukin diftitox | Denileukin diftitox; topical steroids; topical calcipotriol |
| 14 | M/70 | IIB | No clone detectable | 255 | 3.4 | 8 y | Topical steroids | PUVA; MTX; electron beam; ECP |
| 15 | F/53 | IB | No clone detectable | 811 | 1.2 | 5 y | Topical steroids and tacrolimus | PUVA; denileukin diftitox |
| 16 | M/77 | IB | No clone detectable | 443 | 1.1 | 3 y | Topical steroids | Topical steroids |
| 17 | F/30 | IA | No clone detectable | 460 | 0.5 | 3 y | Topical steroids | None |
| 18 | F/44 | IA | No clone detectable | 819 | 4.0 | 5 y | Topical steroids; MTX | Topical steroids |
| 19 | F/57 | IA | Not done | Not done | Not done | 10 y | No therapy (in spontaneous remission for 10 y) | None |
| 20 | F/60 | IA | Not done | Not done | Not done | 5 y | PUVA every 2 weeks | PUVA; topical steroids |
PDN indicates prednisone; MTX, methotrexate; UVB, ultraviolet B; PUVA, Psoralens ultraviolet A; IFN-α, interferon α; and ECP, extracorporeal photochemotherapy.